Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
March 26 2018 - 8:00AM
Business Wire
Including Three Late-Breaking Poster
Presentations
Advaxis, Inc. (NASDAQ:ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, today announced that
results from multiple preclinical studies of its Lm-based antigen
delivery technology will be presented at the American Association
for Cancer Research Annual Meeting 2018 (AACR 2018), April 14-18,
2018 in Chicago.
The following late-breaking research will be presented:
Poster Title:
Neoantigens that fail to elicit measurable T cell responses
following peptide immunization can control tumor growth when
delivered using a Listeria-based immunotherapy platform
Poster Number:
LB-150/17
Session Title:
Late-Breaking Research: Clinical Research
Session Date and Time:
Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)
Authored By:
Advaxis and Amgen
Poster Title:
Targeting frameshift mutations with a
Listeria monocytogenes immunotherapy drives neoantigen-specific
antitumor immunity in the MC38 and CT26 mouse tumor models
Poster Number:
LB-148/15
Session Title:
Late-Breaking Research: Clinical Research
Session Date and Time:
Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)
Authored By:
Advaxis and Amgen
Poster Title:
Targeting shared hotspot cancer mutations
with a Listeria monocytogenes immunotherapy induces potent
anti-tumor immunity
Poster Number:
LB-149/16
Session Title:
Late-Breaking Research: Clinical Research
Session Date and Time:
Monday, April 16, 2018, 1:00 pm - 5:00 pm (CT)
Authored By:
Advaxis
In addition, the following Investigator Sponsored Trial data
will be presented:
Poster Title:
Changes in local and peripheral T cell diversity after HPV E7
antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior
to robotic surgery for HPV-positive oropharyngeal cancer
Poster Number:
5639/10
Session Title:
PO.CL06.11: Vaccines 2
Session Date and Time:
Wednesday, April 18, 2018, 8:00 am - 12:00 pm (CT)
Authored By:
Andrew Sikora, Ph.D., MD, co-director of the Head and Neck Cancer
Program at Baylor College of Medicine
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of
proprietary Lm-based antigen delivery products. These
immunotherapies are based on a platform technology that utilizes
live attenuated Listeria monocytogenes (Lm) bioengineered to
secrete antigen/adjuvant fusion proteins. These Lm-based
strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy and are designed to access and direct antigen
presenting cells to stimulate anti-tumor T cell immunity, activate
the immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot/
cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, and on Form 10-Q for the quarter ended January
31, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180326005188/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.comorRachel Auerbach,
908-325-3898Rauerbach@sternstrategy.comorInvestors:LHA
Investor RelationsAnne Marie Fields,
212-838-3777afields@lhai.com
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2023 to Apr 2024